Elin Haf Davies
Founder

Aparito's Atom5™ eCOA platform digitizes clinical trials by capturing high-frequency data through video assessments, wearable devices, and electronic patient-reported outcomes (ePROs). This technology enables clinical teams to obtain real-time insights from real-world data, enhancing the efficiency and accuracy of trial monitoring.
Raised to date
$1.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Founder
Traditional clinical trials often struggle with infrequent data collection, leading to incomplete or delayed insights into patient health and treatment efficacy. Relying on periodic clinic visits and patient recall introduces potential inaccuracies and limits the ability to capture real-world patient experiences.
Aparito's Atom5™ eCOA platform addresses these challenges by digitizing clinical trials and enabling continuous, high-frequency data capture through various modalities. The platform integrates video assessments, wearable devices, and electronic patient-reported outcomes (ePROs) to provide a comprehensive view of patient health. By leveraging machine learning, Atom5™ delivers real-time insights to clinical teams, enhancing the efficiency and accuracy of trial monitoring while reducing reliance on traditional, less frequent data collection methods. The platform's telemedicine and eConsent capabilities further streamline the clinical trial process.
The primary target audience includes pharmaceutical companies, clinical research organizations (CROs), and academic institutions conducting clinical trials who seek to improve data quality, reduce trial costs, and accelerate drug development timelines.